Lindahl advises Corline Biomedical AB on directed share issue
Lindahl is acting as legal adviser to Corline Biomedical AB (publ) in connection with a directed share issue amounting to approximately SEK 23 million.
Through the share issue, Corline Biomedical will receive approximately SEK 23 million before deduction of issue costs. In addition, the company strengthens its shareholder base with a long-term and international investor, Eiffel Investment Group, to which the issue is directed.
Corline Biomedical develops and sells medical technology solutions. The company's shares are listed on Nasdaq First North Growth Market.
Lindahl's team consists of Mattias Prage and Olle Swärd Brattström.
Do you want to know more? Contact:
Mattias Prage
Partner | AdvokatOlle Swärd Brattström
AssociateCarousel items
-
Cases and transactions
5/6/2026
Lindahl advises Equistone Partners Europe on the sale of BUKO Group
Lindahl, together with Clifford Chance, advises Equistone Partners Europe on the sale of BUKO Group to Groupe Bruxelles Lambert.
-
Knowledge
5/6/2026
A reformed environmental law – what you need to know
Swedish environmental law is undergoing a historic reform. Learn what the new Environmental Permit Authority, revised review tracks and shorter appeal chains mean for your operations – and what you need to do now.
-
News articles
5/4/2026
Johan Norderyd named Practitioner of the Year at the Managing IP Awards
Johan Norderyd has been named the winner in the Sweden Practitioner of the Year (Law Firms) category at the Managing IP EMEA Awards 2026.
-
Portraits
1/20/2026
How I use AI in my daily work as a lawyer
AI is no longer the future – it is everyday reality. Johanna Karlsson, lawyer and senior associate at Lindahl, talks about how AI tools such as Legora have become a natural part of her workflow.
-
Read more news and insights?
